Chad M Barnett

Chad M Barnett

UNVERIFIED PROFILE

Are you Chad M Barnett?   Register this Author

Register author
Chad M Barnett

Chad M Barnett

Publications by authors named "Chad M Barnett"

Are you Chad M Barnett?   Register this Author

10Publications

223Reads

48Profile Views

Cyclin-Dependent Kinase Inhibitors for the Treatment of Breast Cancer: Past, Present, and Future.

Pharmacotherapy 2016 06 28;36(6):652-67. Epub 2016 May 28.

Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/phar.1756DOI Listing
June 2016

Ado-trastuzumab emtansine (T-DM1): a novel antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer.

J Oncol Pharm Pract 2015 Apr 27;21(2):132-42. Epub 2014 Mar 27.

Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1078155214527144DOI Listing
April 2015

Outcomes of children exposed in utero to chemotherapy for breast cancer.

Breast Cancer Res 2014 Dec 30;16(6):500. Epub 2014 Dec 30.

Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Box 1354, Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-014-0500-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4303207PMC
December 2014

Incidence, risk factors, and management of infusion-related reactions in breast cancer patients receiving trastuzumab.

Oncologist 2014 Mar 17;19(3):228-34. Epub 2014 Feb 17.

Department of Pharmacy, Banner MD Anderson Cancer Center, Gilbert, Arizona, USA; Division of Pharmacy and Departments of Biostatistics and NYU Cancer Institute, New York University Langone Medical Center, New York, New York, USA; Breast Medical Oncology, University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2013-0286DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3958456PMC
March 2014

Pertuzumab: a new targeted therapy for HER2-positive metastatic breast cancer.

Pharmacotherapy 2014 Jan 5;34(1):60-71. Epub 2013 Aug 5.

Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/phar.1338DOI Listing
January 2014

Evaluation of pharmacist-provided medication therapy management services in an oncology ambulatory setting.

J Am Pharm Assoc (2003) 2012 Mar-Apr;52(2):170-4

Division of Pharmacy, Unit 377, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030-4009, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1331/JAPhA.2012.11171DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3868215PMC
June 2012

Everolimus: targeted therapy on the horizon for the treatment of breast cancer.

Authors:
Chad M Barnett

Pharmacotherapy 2012 Apr;32(4):383-96

Department of Breast Medical Oncology, Division of Pharmacy, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/j.1875-9114.2012.01084.x
Publisher Site
http://dx.doi.org/10.1002/j.1875-9114.2012.01084.xDOI Listing
April 2012

Survival data of patients with anthracycline- or taxane-pretreated or resistant metastatic breast cancer.

Authors:
Chad M Barnett

Pharmacotherapy 2009 Dec;29(12):1482-90

Department of Breast Medical Oncology, Division of Pharmacy, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1592/phco.29.12.1482DOI Listing
December 2009